Affimed Announces Upcoming Conference Call
Affimed N.V. (Nasdaq: AFMD), a pioneering clinical-stage immuno-oncology firm, has exciting news to share regarding its innovative approach to cancer treatment. The company is set to host a conference call to showcase clinical data from the AFM24-102 trial. This study focuses on the potential of the AFM24 innate cell engager combined with Atezolizumab, targeting non-small cell lung cancer. This announcement represents a significant step in the company's mission to enhance patient care in oncology.
Details of the Conference Call
The much-anticipated conference call will take place on a Tuesday at 8:30 a.m. EST / 14:30 CET. Interested parties can look forward to a comprehensive review of the trial results, reflecting Affimed's commitment to transparency and stakeholder engagement in its clinical developments. Participants can join either via phone or through a live audio webcast available on the company’s website. To participate by phone, attendees will need to register online, ensuring they receive the appropriate dial-in information and access codes necessary for the event.
Best Practices for Participants
To ensure a smooth experience with no delays, Affimed encourages participants to join the call at least 15 minutes early. This proactive measure allows for addressing any technical issues before the call commences. Furthermore, the company will provide a recording of the webcast for those who wish to review the information discussed during the call. This replay will remain accessible for 30 days following the event, making it convenient for stakeholders to catch up at their leisure.
About Affimed and Its Innovations
Affimed N.V. focuses on disrupting traditional cancer treatments with its novel immuno-oncology solutions. The essence of the company’s philosophy lies in harnessing the innate immune system to combat cancer more effectively. Through its innovative innate cell engagers (ICE®), Affimed targets tumor cells efficiently, allowing for a highly selective and potent anti-tumor response.
The ROCK® Platform
The innate cell engagers are developed using the company’s proprietary ROCK® platform. This state-of-the-art technology consistently creates tailored molecules designed to activate and empower the body’s immune cells, specifically targeting both hematologic and solid tumors. The practicality of ICE® molecules as either monotherapy or in combination with existing treatments enhances their therapeutic potential, promising improved outcomes for patients.
Company's Leadership and Vision
Headquartered in Mannheim, Germany, Affimed is directed by a seasoned team of professionals from the biotechnology and pharmaceutical sectors. This diverse leadership group is united by a powerful vision: to prevent cancer from compromising patients’ lives. Their strategic initiatives aim to reshape the landscape of cancer therapy and provide hope through innovative research and development efforts.
Affimed's Commitment to Patients
Ultimately, Affimed is dedicated to restoring patients' natural ability to fight cancer while complementing their existing treatment journey. The ongoing clinical trials, including the current focus on AFM24 and Atezolizumab, represent vital milestones in this commitment. As the company continues to develop its pipeline and expand partnerships, it actively seeks opportunities to enhance patient outcomes and advance the field of oncology.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to review clinical data from the AFM24-102 trial involving AFM24 in combination with Atezolizumab for treating non-small cell lung cancer.
How can participants access the conference call?
Participants can join the conference call via phone or through a live audio webcast on Affimed’s website. Registration is required for phone access to receive dial-in details.
How long will the webcast replay be available?
The replay of the webcast will be available for 30 days following the live event, providing access to those who couldn’t attend in real time.
What is the significance of the AFM24-102 trial?
The AFM24-102 trial explores the efficacy of combining AFM24 with Atezolizumab, which could provide new insights and potential benefits for patients with non-small cell lung cancer.
Who leads Affimed's innovative research?
Affimed is led by an experienced team in biotechnology and pharmaceuticals, all committed to transforming cancer treatment through advanced immuno-oncology solutions.
